science wire

« BACK

Pharmacology



Results 801 - 850 of 1530.


Health - Pharmacology - 12.12.2016
Novartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicines
SMS for Life 2.0 launches for the first time in Kaduna State, Nigeria's third most populous region, in collaboration with the Kaduna State Ministry of Health   Program uses smartphones and tab

Health - Pharmacology - 09.12.2016
Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozole
Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozole MONALEESA-2 analyses demonstrate superior PFS with LEE011 plus letrozole in pre-defined patient subgroups - from de novo to bone, liver and lung metastases - compared to letrozole alone   LEE011 plus letrozole reduced risk of progression or death by 55% over letrozole alone in de

Health - Pharmacology - 08.12.2016
The R. Geigy Foundation honours efforts to overcome ’neglected tropical diseases
Giovanna Raso and Jean Coulibaly are the awardees of the R. Geigy-Award 2016 and will share a CHF 20,000 prize in honour of their efforts to fight neglected helminth infections in West Africa.

Health - Pharmacology - 08.12.2016
Back to life
«A few months after the proton treatment was over, I realised that I could see more and more. Just dimly, it's true, but I could see! That was sensational!» More than a year ago, Gabi Meier* was treated with proton therapy at the Paul Scherrer Institute PSI.

Pharmacology - Health - 08.12.2016
Novartis’ Ultibro Breezhaler improved lung function and COPD symptoms after direct switch from previous treatment
Ultibro Breezhaler improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid-containing combination therapies   Results further support the 2017 GOLD recommendations that dual bronchodilation should be the foundation treatment for the majority of symptomatic COPD patients   Data from the pragmatic CRYSTAL study showcased for the first time at the 2016 British Thoracic Society Winter Meeting in Lond

Health - Pharmacology - 07.12.2016
Roche’s Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer
Roche's Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer Approval based on two large Phase III studies including GOG-0213 that showed a five month overall survival difference for women with platinum-sensitive recurrent ovarian cancer on Avastin plus chemotherapy compared to chemotherapy alone In the United States, Avastin is now approved for nine distinct uses across six different type

Health - Pharmacology - 07.12.2016
Novartis’ Lucentis received EU approval in new indication - Lucentis the only treatment available for a wide range of CNV conditions
Novartis' Lucentis received EU approval in new indication - Lucentis the only treatment available for a wide range of CNV conditions The European Commission approved Lucentis to treat patients for vi

Pharmacology - Health - 06.12.2016
Novartis announces Zykadia first-line study results showing 16.6 month progression-free survival in patients with ALK+ advanced NSCLC
Patients without brain metastases at diagnosis experienced median progression-free survival of 26.3 months, the longest seen in a global Phase III study in ALK+ NSCLC   Patients with measurable brain metastases in the Zykadia arm experienced an intracranial response rate of more than 70%   Data will be used to support global regulatory submissions for first-line use of Zykadia in ALK+ advanced NSCLC patients - Novartis today announced res

Pharmacology - Health - 05.12.2016
New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product
ASSIST-FL trial demonstrates equivalent safety, efficacy, pharmacokinetics and pharmacodynamics of Sandoz proposed biosimilar rituximab (GP2013) to the reference product Interim data in over 600 adults show potential of GP2013 as an alternative rituximab Sandoz proposed biosimilar rituximab is the company's first monoclonal antibody candidate Holzkirchen, December 5, 2016 - Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced data from the ASSIST-FL trial.

Health - Pharmacology - 05.12.2016
Novartis data shows Treatment-free Remission rates are consistently above 50% regardless of reason for switch to Tasigna from Glivec
ENESTop post-hoc analysis provides further insights into Treatment-free Remission (TFR) among Ph+ CML switch patients The Tasigna TFR trials, including ENESTop, demonstrate our continued commitment to the CML community - Novartis today announced at the 58th American Society of Hematology (ASH) Annual Meeting & Exposition new data from the Tasigna (nilotinib) ENESTop Treatment-free Remission (TFR) study, which demonstrate that TFR rates are c

Pharmacology - Health - 05.12.2016
Roche’s Gazyva/Gazyvaro Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to MabThera/Rituxan
Roche's Gazyva/Gazyvaro Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to MabThera/Rituxan First Phase III study to show superior progression-free survival compared to MabThera/Rituxan-based standard of care treatment for most common slow-growing form of non-Hodgkin lymphoma Results were presented during the Plenary Scientific Session at 58th American Society of Hema

Health - Pharmacology - 04.12.2016
Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL
82% (41 of 50) of patients achieved complete remission or complete remission with incomplete blood count recovery in interim analysis of Novartis study (ELIANA) ELIANA, the first global CAR T'cell tr

Pharmacology - Health - 03.12.2016
Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study
SEG101 reduced annual rate of sickle cell-related pain crises (SCPC) by 45.3% compared to placebo in patients with or without hydroxyurea therapy   SEG101 is a potential new disease-modifying, preventive treatment option for patients with SCPC; first in nearly 20 years   Data being highlighted in ASH 2016 media briefing, presented at Plenary Scientific Session and published simultaneously in The New England Journal of Medicine Basel, Dece

Health - Pharmacology - 29.11.2016
Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda
Rwanda becomes third country to launch Novartis Access portfolio against chronic diseases with first deliveries planned in early 2017 Since September 2015, Novartis Access has delivered more than 100

Health - Pharmacology - 28.11.2016
Successfully Treating Genetically Determined Autoimmune Enteritis
Using targeted immunotherapy, doctors have succeeded in curing a type of autoimmune enteritis caused by a recently discovered genetic mutation. This report comes from researchers at the Department of Biomedicine of the University of Basel and University Hospital Basel. Their results raise new possibilities for the management of diarrhea, which is often a side effect of melanoma treatment.

Health - Pharmacology - 21.11.2016
Novartis commends publication of major report which recommends broad use of dual bronchodilators to treat COPD
2017 GOLD report recommends the first-line use of dual bronchodilators, such as Ultibro Breezhaler , in the treatment of the majority of symptomatic COPD patients   Bronchodilation regarded as the fo

Pharmacology - Health - 21.11.2016
Novartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD)
Deal followed results of Phase II SUSTAIN study of SelG1 in reduction of vaso-occlusive pain crises, a major complication of SCD with limited treatment options   Results of SUSTAIN will be presented

Pharmacology - Health - 18.11.2016
Innovative study with three treatment switches confirms Sandoz biosimilar etanercept has equivalent efficacy to originator
No clinically meaningful differences between biosimilar etanercept and the originator product in safety and efficacy over 52 weeks   Innovative study design demonstrates switching between biosimilar etanercept and the originator product has no impact on safety and efficacy   Sandoz biosimilar etanercept was approved by the FDA* in August 2016 and is currently under review by the EMA ** Holzkirchen, November 18, 2016 - Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced the publication of the EGALITY study in the British Journal of Dermatology .

Health - Pharmacology - 17.11.2016
Antibiotic resistance: Swiss physicians, vets, biologists and environmental researchers are working together to find solutions
Antibiotic resistance: Swiss physicians, vets, biologists and environmental researchers are working together to find solutions
The SNSF is launching the National Research Programme "Antimicrobial Resistance", which aims to develop new solutions to ensure that antibiotics remain effective. Worldwide, more and more pathogens are becoming resistant to today's antibiotics. The aim of European Antibiotic Awareness Day on 18 November 2016 is to highlight the fact that medicines are losing their effectiveness as a result and that once easy-to-treat infections are turning into deadly diseases.

Pharmacology - Health - 16.11.2016
Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer
First results from global registrational trial of CAR T'therapy, CTL019, in pediatric relapsed/refractory acute lymphoblastic leukemia  Sub-group analyses from pivotal MONALEESA-2 trial of LEE011 (ri

Pharmacology - Health - 16.11.2016
Novartis announces AMG 334 significantly reduces monthly migraine days in second pivotal Phase III episodic migraine study
STRIVE, the first six-month placebo-controlled study of AMG 334 (erenumab) in migraine, met the primary endpoint, showing a statistically significant reduction in monthly migraine days versus placebo

Health - Pharmacology - 15.11.2016
New analysis of Novartis’ Entresto data shows long-term benefits on heart failure readmissions and total cardiovascular deaths
Entresto reduced the risk of first and subsequent events of heart failure hospitalizations and cardiovascular deaths following heart failure hospitalization by 20%-24% compared to enalapril   These f

Health - Pharmacology - 15.11.2016
Roche launches imCORE, a global network of cancer immunotherapy centers of excellence
Roche launches imCORE, a global network of cancer immunotherapy centers of excellence Research network of 21 academic centers from around the world to access and share technology, data and expertise

Pharmacology - Health - 14.11.2016
Novartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3 years including patient-reported pain
Cosentyx data show sustained improvements in the signs and symptoms of psoriatic arthritis (PsA) in approximately 80% of patients over 3 years *   New data show that with Cosentyx the high ACR response rates are consistently maintained in PsA, with no reduction from Year 1 to Year 3   New head-to-head clinical trials planned in ankylosing spondylitis (AS) and PsA to compare Cosentyx versus Humira **/*** The digital press release with multimedia

Pharmacology - Health - 14.11.2016
Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis
Priority Review based on data from the largest clinical trials conducted to date in each indication , Designation will shorten FDA expected review time to within six months ; EMA also accepted the PK

Health - Pharmacology - 14.11.2016
Novartis improves ranking in 2016 Access to Medicine Index
Novartis ranks third in 2016 ranking   Company tops the industry in access-to-medicine management and capacity building   Novartis integrated access strategy addressing all income segments stands out

Pharmacology - Health - 03.11.2016
Roche showcases new clinical data across a variety of blood diseases at American Society of Hematology 2016 Annual Meeting
Roche showcases new clinical data across a variety of blood diseases at American Society of Hematology 2016 Annual Meeting New results from the phase III GALLIUM study which compared Gazyva/Gazyvaro

Health - Pharmacology - 02.11.2016
Roche to present new data on medicines for autoimmune diseases and severe inflammatory disorders at the 2016 ACR/ARHP Annual Meeting
Roche to present new data on medicines for autoimmune diseases and severe inflammatory disorders at the 2016 ACR/ARHP Annual Meeting 15 oral presentations from 17 abstracts across six autoimmune cond

Health - Pharmacology - 01.11.2016
Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer
Priority Review based on Phase III MONALEESA-2 trial, which showed LEE011 plus letrozole, as initial treatment for advanced breast cancer, significantly extended progression-free survival compared to

Health - Pharmacology - 31.10.2016
Novartis Wins Two Prestigious Prix Galien Foundation Awards; Gleevec recognized as "Discovery of the Decade" for Best Pharmaceutical Product, Cosentyx as Best Biotechnology Product
Novartis Wins Two Prestigious Prix Galien Foundation Awards; Gleevec recognized as "Discovery of the Decade" for Best Pharmaceutical Product, Cosentyx as Best Biotechnology Product Basel, October 31,

Pharmacology - Business / Economics - 25.10.2016
Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters Q3 net sales (-1% cc and USD) broadly in line wit

Pharmacology - Health - 19.10.2016
FDA approves Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) for people with a specific type of metastatic lung cancer
FDA approves Roche's cancer immunotherapy TECENTRIQ (atezolizumab) for people with a specific type of metastatic lung cancer First and only anti-PD-L1 cancer immunotherapy approved by the FDA for met

Health - Pharmacology - 18.10.2016
Soil-Transmitted Helminthiasis Advisory Committee Convenes at Swiss TPH
Soil-Transmitted Helminthiasis Advisory Committee convenes at Swiss TPH This year's annual meeting of the Soil-Transmitted Helminthiasis Advisory Committee, chaired by Jürg Utzinger, is hosted at Swiss TPH.

Health - Pharmacology - 18.10.2016
Alcon launches the CyPass Micro-Stent at the American Academy of Ophthalmology (AAO) 2016 annual meeting
Alcon to host first live training program on the use of the CyPass Micro-Stent, a minimally invasive glaucoma surgical device to treat cataract patients with mild to moderate primary open-angle glauc

Pharmacology - Computer Science / Telecom - 13.10.2016

Health - Pharmacology - 10.10.2016
Reviewing the treatment of differences of sex development
Reviewing the treatment of differences of sex development
The SNSF is providing funding for University Children's Hospital Zurich's scientific review of the treatment of children with differences of sex development (DSD children). They used to be called hermaphrodites and intersexuals. From the 1950s onwards, it was customary for children and newborns with no clear biological gender to be assigned their "true" gender as soon as possible by exploiting pharmacotherapy or by surgically operating on them.

Health - Pharmacology - 09.10.2016
Novartis ALK+ metastatic NSCLC therapy Zykadia extends progression-free survival beyond 18 months in Phase II study
Progression-free survival (PFS) in ALKi-naïve patients is consistent with results previously reported from Phase I ASCEND-1 study Phase II study also showed overall response rate of 63.3% in A

Health - Pharmacology - 08.10.2016
Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care
Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care LEE011 (ribociclib) plus letrozole reduced the risk of progression or death by 44% over letrozole alone, significantly extending progression-free survival (PFS) across all patient subgroups   Results showed that the combination significantly improved tumor

Health - Pharmacology - 08.10.2016
Novartis’ Tafinlar (dabrafenib) + Mekinist (trametinib) demonstrate superior overall survival benefit in advanced melanoma patients at three-year follow up
Novartis' Tafinlar (dabrafenib) + Mekinist (trametinib) demonstrate superior overall survival benefit in advanced melanoma patients at three-year follow up Latest data confirm an estimated 45% of pat

Health - Pharmacology - 07.10.2016
Zurich aims to extend high profile research on skin
Zurich aims to extend high profile research on skin
A new interdisciplinary, large-scale project from the "Hochschulmedizin Zürich" network focuses on skin research in Zurich.

Pharmacology - Health - 05.10.2016
FDA grants breakthrough therapy designation for Roche’s Actemra/RoActemra in giant cell arteritis, a form of vasculitis
FDA grants breakthrough therapy designation for Roche's Actemra/RoActemra in giant cell arteritis, a form of vasculitis Roche recently announced positive results from a Phase III GCA clinical trial Fourteenth Breakthrough Therapy designation for Roche medicines There have been no therapies approved for GCA in more than 50 years Roche , announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation status to Actemra/RoActemra (tocilizumab) for giant cell arteritis (GCA), a chronic, potentially life-threatening autoimmune condition.

Health - Pharmacology - 04.10.2016
New chemical compound shows promising results against drug-resistant malaria parasites
The new chemical compound ACT-451840 is highly effective against most deadly malaria parasites in humans. It is also active against those parasites that have developed resistance against the standard therapies. The findings, published today in the journal PLOS Medicine, come from the Swiss Tropical and Public Health Institute (Swiss TPH) in collaboration with partners from industry and academia.

Pharmacology - Health - 04.10.2016
US FDA grants Breakthrough Therapy Designation for Roche’s Alecensa (alectinib) for first-line treatment of people with ALK-positive NSCLC
US FDA grants Breakthrough Therapy Designation for Roche's Alecensa (alectinib) for first-line treatment of people with ALK-positive NSCLC This second Alecensa Breakthrough Therapy Designation granted is based on phase 3 J-ALEX study Roche announced today that it has received a second Breakthrough Therapy Designation (BTD) from the United States Food and Drug Administration (FDA) for its ALK inhibitor, Alecensa (alectinib).

Health - Pharmacology - 03.10.2016
First phase III data on Roche’s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress
First phase III data on Roche's TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress - Superiority results from the phase III OAK study comparing Tecentriq to chemotherapy in a difficult to treat type of lung cancer will be highlighted at the ESMO Presidential Symposium - Investigational cancer immunotherapy-based combination approaches across a range of cancer types to be showcased during the con

Pharmacology - Health - 01.10.2016
Novartis late-breaking data show Cosentyx delivers high and long-lasting skin clearance over 4 years for psoriasis patients
Cosentyx delivers long-lasting clear or almost clear skin (PASI 90 to PASI 100) in the vast majority of patients and continues to show a favorable safety profile over 4 years New data show that with Cosentyx almost 100% of PASI 90 and PASI 100 response rates are maintained from Year 1 to Year 4   Cosentyx significantly superior to Stelara in delivering long-lasting skin clearance in psoriasis over 52 weeks, confirms new JAAD publication The digi

Pharmacology - Health - 28.09.2016
Sandoz invites young entrepreneurs to enter Sandoz HACk, a global competition to help solve healthcare access challenges
Despite significant advances made by modern medicine, universal access to healthcare is still arguably the single largest unmet medical need   Sandoz "HACk" - Healthcare Access Challenge - is a compe

Pharmacology - Health - 28.09.2016
Novartis announces Phase III study shows AMG 334 significantly reduces monthly migraine days in people with episodic migraine
ARISE, first pivotal Phase III study of AMG 334 (erenumab) in episodic migraine prevention, met primary endpoint, showing a statistically significant reduction in monthly migraine days vs placebo   People with episodic migraine experience up to 14 migraine days each month and lose a substantial part of their lives to this debilitating disease   AMG 334 is being co-developed by Novartis and Amgen Basel, September 28, 2016 - Novartis today announc

Pharmacology - Health - 23.09.2016
Novartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic Fever Syndrome conditions
Ilaris (canakinumab) is the first and only US FDA-approved biologic treatment for patients with TRAPS, HIDS/MKD and FMF disease   These three simultaneous approvals conducted under FDA Priority Revie

Health - Pharmacology - 23.09.2016
Novartis announces positive top-line results from ASCEND-4, a Phase III trial of Zykadia in untreated adult ALK+ NSCLC patients
In a Phase III clinical study, Zykadia extended progression-free survival (PFS) when compared with standard chemotherapy, including maintenance    Novartis is moving forward with global regulatory su

This site uses cookies and analysis tools to improve the usability of the site. More information. |